EDGAR·FLOW

IMMUNIC, INC. — Form 8-K

Filed November 13, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Immunic reported Q3 2026 results with $131.96M cash (up from $15.48M at year-end 2025, funded by February 2026 private placement). Lead program vidofludimus calcium in twin Phase 3 ENSURE trials (1,121 and 1,100 relapsing MS patients enrolled) remains on schedule for December 2026 top-line data; if positive, NDA submission planned mid-2027 with potential approval in 2028. Phase 3 PROTECT-MS progressive MS trial initiating with first patient expected H1 2027. Company added Chief Data/Digital Officer (Sept 2026) and Chief People Officer (Oct 2026); board added CFO Elena Ridloff. Nine-month operating expenses reached $111.9M; net loss $109.0M ($2.83/share) on 38.5M weighted-average shares. Cash runway extends to late 2027.
Why this rating

Phase 3 readout in weeks is transformational catalyst for $83M company; December data could validate NDA pathway or destroy value. Near-term binary event materially affects trajectory.

Tradability signal
NO TRADE

No trade: positive news with only +0.5% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.36% over 4 hrs, n=469). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$7.67 ▼ 2.54%
at our read · unknown
$7.87
+10 min · unknown
$7.71 ▼ 2.10%
+30 min · unknown
$7.56 ▼ 3.94%
+1 hr · unknown
$7.72 ▼ 1.91%
+4 hrs · unknown
$7.70 ▼ 2.15%

The stock had already moved +2.60% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ IMUX · stock on Yahoo Finance ↗

See more from November 13, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.